Phase 5 of the Cancer Gene Index Project Begins


By Allison Proffitt

June 25, 2008 | Sophic has announced $1.3 million of funding from the National Cancer Institute to complete the Cancer Gene Index Project over the next 12 months. Sophic started the project in June 2004 with the goal of mining 8.8 million Medline abstracts to identify suspected cancer genes and manually annotate gene-disease and gene-compound relationships. So far 4,658 cancer genes have been made publically available on the NCI website.

“We’ve completed four years of work and this phase is the completion phase, which means we will have completely analyzed and annotated the 6,610 identified cancer genes with manual annotations for role codes and evidence codes,” Patrick Blake, Sophic’s CEO told Bio-IT World. “I just attended the caBIG conference and they are identifying this dataset as the backbone for cancer research across the cancer community. We’re proud and we’re thrilled to be able to offer this asset to people who are fighting this terrible disease.”

The fifth phase of the project, announced on Monday, will bring the total number of cancer related genes indexed to 6,610. Sophic has completed the work in conjunction with NCI and Biomax Informatics AG of Munich, Germany in what Blake calls “a true collaboration” using Biomax’ BioLT literature mining tool. “We developed a ‘factory assembly line’ methodology that allows the automated text mining results to be fed into the scientific team who curate and annotate the information in an efficient, quality-controlled, work-flow process,” said Klaus Heumann, CEO of Biomax. The phase-based strategy has been designed so that “nothing is missed” and that all cancer genes, cancer types, and compounds and treatments related to cancer genes are examined.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.